Professor Hans Wandall review published in Nature
Collaboration to Accelerate Next-Generation Cancer Treatment
GO Therapeutics Scientific Co-Founder & Chief Scientific Officer Hans Wandall, M.D., Ph.D. co-authors article published in British Journal of Cancer.
Under the terms of the agreement, GO will grant Roche a worldwide, exclusive license for antibodies generated to address a novel cancer-specific target to develop and commercialize a new glycotargeting bispecific antibody.
Strategic investment to help accelerate antibody development programs against novel solid tumor targets.